{
  "study": {
    "nct_id": "NCT01907900",
    "title": "Pirfenidone in Progressive Fibrosing ILD",
    "sponsor": "Genentech, Inc.",
    "status": "Completed",
    "phase": "Phase 2",
    "indication": "Progressive fibrosing interstitial lung disease",
    "enrollment": 253,
    "primary_outcome": "Change in FVC over 24 weeks",
    "result_summary": "Pirfenidone slowed the decline in forced vital capacity versus placebo.",
    "references": [
      {
        "type": "journal",
        "citation": "Maher TM et al. Lancet Respir Med. 2020;8(2):147-157.",
        "url": "https://clinicaltrials.gov/study/NCT01907900"
      }
    ]
  }
}
